Immunotherapy comparable to chemo for some advanced stomach cancers

(June 4, 2019)

An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe. For some, the immune-boosting treatment offered improved survival compared to standard treatment. The... Continue Reading


Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

(June 3, 2019)

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor... Continue Reading


FDA approves lenalidomide for follicular and marginal zone lymphoma

(May 30, 2019)

On May 28, 2019, the Food and Drug Administration approved lenalidomide (REVLIMID®, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). The MAGNIFY... Continue Reading


Piqray® approved for the treatment of postmenopausal women with breast cancer

(May 29, 2019)

The US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2... Continue Reading


Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

(May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading


Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

(May 7, 2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About... Continue Reading


FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

(May 7, 2019)

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at... Continue Reading


Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer

(May 6, 2019)

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness... Continue Reading


Ice Chips May Be The Easiset Way to Reduce Mucositis From Cancer Treatment

(May 3, 2019)

A new study in the April 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that oral cryotherapy reduce mucositis related side effects. Ice chips or “cryotherapy” has long been used to reduce the intensity of mouth... Continue Reading


ASCO Guideline: Oxaliplatin Adjuvant Therapy for Stage III Colon Cancer May Be Reduced in Select Patients

(May 1, 2019)

The American Society of Clinical Oncology (ASCO) has released a new guideline that states that patients with clinically low-risk stage III colon cancer should have the option of receiving 3 months of adjuvant oxaliplatin-based chemotherapy. For patients... Continue Reading


37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer

(April 30, 2019)

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer... Continue Reading


FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

(April 16, 2019)

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy,... Continue Reading


« Previous PageNext Page »